Furthermore, the triplet regimen zanubrutinib, obinutuzumab, and venetoclax (BOVen) have been assessed in a phase-two trial involving 25 treatment-naïve MCL patients, all of whom had TP53 mutations [73]. This evidence concerns the gene TP53 and mantle cell lymphoma.